Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progres

Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung CancerCompany Secured up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC; Expected Cash Runway Thr...

Related Keywords

United States ,American ,Ajay Munshi ,Nate Liabraaten ,Secura Bio ,Elisa Buffington ,Brian Stuglik ,Chugai Pharmaceutical Co Ltd ,Amgen ,Drug Administration ,Company Annual Report On Form ,Exchange Commission ,American Association For Cancer Research ,Corporate Development ,Secura Bio Inc ,Group Limited ,Corporate Communications ,Verastem Oncology Press ,Raf And Mek Program ,Oxford Finance ,Enrollment Completed ,Selection Phases ,Low Grade Serous Ovarian Cancer ,Non Dilutive Funding ,Expected Cash Runway Through ,Support Continued Development ,Potential Commercial Launches ,Verastem Oncology ,Chief Executive Officer ,Grade Serous Ovarian Cancer ,American Association ,Cancer Research ,Non Small Cell Lung Cancer ,National Medical Products Administration ,Breakthrough Therapy ,Annual Report ,Oncology Press ,Recurrent Low Grade Serous Ovarian ,Accessed May ,Consolidated Statements ,